Unknown

Dataset Information

0

Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.


ABSTRACT: Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, modified Mendelian randomization approach to investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis.Using data from the Advanced Study of Aortic Pathology, we identified the single-nucleotide polymorphism in PLA2G5 showing the strongest association with PLA2G5 mRNA expression levels as a proxy for sPLA2-V levels. We tested the association of this SNP with sPLA2 activity and CHD events in 4 prospective and 14 case-control studies with 27 230 events and 70 500 controls. rs525380C>A showed the strongest association with PLA2G5 mRNA expression (P=5.1×10(-6)). There was no association of rs525380C>A with plasma sPLA2 activity (difference in geometric mean of sPLA2 activity per rs525380 A-allele 0.4% (95% confidence intervals [-0.9%, 1.6%]; P=0.56). In meta-analyses, the odds ratio for CHD per A-allele was 1.02 (95% confidence intervals [0.99, 1.04]; P=0.20).This novel approach for single-nucleotide polymorphism selection for this modified Mendelian randomization analysis showed no association between rs525380 (the lead single-nucleotide polymorphism for PLA2G5 expression, a surrogate for sPLA2-V levels) and CHD events. The evidence does not support a causal role for sPLA2-V in CHD.

SUBMITTER: Holmes MV 

PROVIDER: S-EPMC4212409 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.

Holmes Michael V MV   Exeter Holly J HJ   Folkersen Lasse L   Nelson Christopher P CP   Guardiola Montse M   Cooper Jackie A JA   Sofat Reecha R   Boekholdt S Matthijs SM   Khaw Kay-Tee KT   Li Ka-Wah KW   Smith Andrew J P AJ   Van't Hooft Ferdinand F   Eriksson Per P   Franco-Cereceda Anders A   Asselbergs Folkert W FW   Boer Jolanda M A JM   Onland-Moret N Charlotte NC   Hofker Marten M   Erdmann Jeanette J   Kivimaki Mika M   Kumari Meena M   Reiner Alex P AP   Keating Brendan J BJ   Humphries Steve E SE   Hingorani Aroon D AD   Mallat Ziad Z   Samani Nilesh J NJ   Talmud Philippa J PJ  

Circulation. Cardiovascular genetics 20140221 2


<h4>Background</h4>Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly quantifies sPLA2-V levels,  ...[more]

Similar Datasets

| S-EPMC3142130 | biostudies-literature
| S-EPMC4789498 | biostudies-literature
| S-EPMC3826105 | biostudies-literature
| S-EPMC2656657 | biostudies-literature
| S-EPMC3234375 | biostudies-literature
| S-EPMC6557629 | biostudies-literature
| S-EPMC2758888 | biostudies-literature
| S-EPMC5495423 | biostudies-literature
| S-EPMC3119755 | biostudies-literature
| S-EPMC7024236 | biostudies-literature